CAMBRIDGE, Mass--In a phase II study, Genetics Institute's recombinant
human interleukin-11 (rhIL-11) restored platelets in throm-bocytopenic
patients undergoing cancer chemotherapy to the extent that significantly
fewer rhIL-11 treated patients required platelet transfusions,
compared to placebo.
Based on this favorable outcome, the company plans to begin a
phase III study by the end of this year.